Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up

Journal of the National Cancer Institute

Volumn 96, Issue 22, 2004, Pages 1714-1717

  Zorat, Pier Luigi ^a   Paccagnella, Adriano ^b,i   Cavaniglia, Giancarlo ^c   Loreggian, Lucio ^c   Gava, Alessandro ^a   Mione, Carlo Alberto ^b   Boldrin, Fanny ^e   Marchiori, Carlo ^a   Lunghi, Francesco ^f   Fede, Antonella ^a   Bordin, Alessandro ^g   Da Mosto, Maria Cristina ^c   Sileni, Vanna Chiarion ^c   Orlando, Antonio ^a   Jirillo, Antonio ^h   Tomio, Luigi ^c   Pappagallo, Giovanni Luigi ^d   Ghi, Maria Grazia ^b  

^a OSPEDALE CA FONCELLO   (Italy)

^b Ctro Regionale Specializzato P   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d Medical Oncology Department   (Italy)

^e Otorinolaryngology Department   (Italy)

^f Ospedale di Monselice   (Italy)

^g SAN MARTINO HOSPITAL   (Italy)

^h Legnago Hospital   (Italy)

ⁱ Department of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9744257104     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh306     Document Type: Article

References (31)

1. Million RR. Cancer of the head and neck. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia (PA): JB Lippincott; 1992. p. 396-420.
2. Munrow AJ. A systematic review of chemotherapy trials in head and neck cancer [abstract]. Eur J Cancer 1999;35(Suppl 4/9): 602a.
3. Pignon JP, Bourhris J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355: 949-55.
4. Bernier J, Domenge C, Ozsahin, M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
5. Cooper SJ, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxinan SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
6. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
7. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-90.
8. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
9. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9.
10. Paccagnella A, Pappagallo GL, Segati R, Zorat P, Cavaniglia G, Fosser VP, et al. Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am J Clin Oncol 1990;13:194-8.
11. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della testa e del Collo. J Natl Cancer Inst 1994;86: 265-72.
12. International Union Against Cancer (UICC). TNM classification of malignant tumors. 3rd ed. Geneva (Switzerland): UICC; 1978.
13. World Health Organization (WHO). Handbook for reporting results of cancer treatment. No. 48. Geneva (Switzerland): WHO; 1979.
14. Dalley D, Beller E, Aroney R, Dewar J, Page J, Philip R, et al. The value of chemotherapy prior to definitive local therapy in patients with locally advanced squamous cell carcinoma of the head and neck [abstract 856]. Proc ASCO 1995;44:297.
15. Lewin F, Damber L, Jonsson H, Andersson T, Berthelsen A, Biorklund A, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997; 43:23-8.
16. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000;83:1594-8.
17. Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003,21:327-33.
18. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
19. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
20. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338: 1798-804.
21. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64.
22. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998;16;1331-9.
23. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-11.
24. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (op TPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002;25:153-9.
25. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Le Bouder C, Castelijns JA, et al. Phase I-II study with docetaxel, cisplatin and 5 fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck [abstract 1524]. Proc ASCO 1999;18.
26. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, et al. Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24;227-31.
27. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluoruracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-104.
28. Hitt R, Lopez-Pousa A, Rodriguez M, Martinez-Trufero J, Cervantes A, Carles J, et al. Phase III study comparing cisplatin and 5 fluorouracil versus cisplatin + 5-fluorouracil and paclitaxel as induction therapy in locally advanced head and neck cancer [abstract 1997]. Proc ASCO 2003;22.
29. Pignon JP, Syz N, Posner M, Olivares R, Le Lann L, Yver A, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004;15:331-40.
30. Vermorken J, Remenar E, Van Herpen C, Germa Lluch J, Stewart S, Gorlia T, et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel + PF (TPF) as neoadjuvant chemotherapy for non resectable locally advanced squamous cell carcinoma of the head and neck: a phase III trial of the EORTC Head and Neck Cancer Group [abstract 5508]. J Clin Oncol 2004;22(14S):490S.
31. Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys 2004;59:481-7.